Caroline Berube

Hematologist, Medical oncologist, Leukemia specialist

Clinical Associate Professor, Medicine - Hematology

Hematology Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Anticoagulation Clinic

  • 900 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-725-4932
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Board Certification: Medical Oncology, Royal College of Physicians and Surgeons of Canada (1990)

Board Certification: Hematology, Royal College of Physicians and Surgeons (1989)

Board Certification: Internal Medicine, Royal College of Physicians and Surgeons of Canada (1988)

Residency: Laval University (1987) Canada

Internship: Laval University (1984) Canada

Fellowship: McMaster University (1991) Canada

Fellowship: The University of British Columbia (1990) Canada

Oncology, University of BC, Canada, Medical Oncology (1990)

Board certification, Hematology, Canadian Hematology Board (1989)

Fellowship: University of Montreal (1989) Canada

Hematology, University of Montreal, Canada, Hematology (1989)

Medical Education: Laval University (1983) Canada

F.R.C.P.(C), Internal Medicine, Canadian Board (1987)

M.D., Laval University, Canada, Medicine (1984)

Administrative Appointments

Medical Director, Oral Anticoagulation Clinic, Stanford Hospital and Clinics (2004 - Present)

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., & Medeiros, B. C. (2013). Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. HAEMATOLOGICA, 98(4), 591-596.

Accessory splenules in autoimmune hemolytic anemia.
Logan, A., Berube, C., & Gotlib, J. (2013). Accessory splenules in autoimmune hemolytic anemia. American journal of hematology, 88(2), 156-?.

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., & Medeiros, B. C. (2012). Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. LEUKEMIA, 26(5), 893-901.

Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., & Coutre, S. E. (2012). Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 30-37.

Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer
Lee, R., Wen, A., & Berube, C. (2011). Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 68(9), 814-817.

Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., & Medeiros, B. C. (2010). Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. AMERICAN JOURNAL OF HEMATOLOGY, 85(11), 877-881.

Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9
Sagrieya, H., Berube, C., Wen, A., Ramakrishnan, R., Mir, A., & Altman, R. B. (2010). Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. PHARMACOGENETICS AND GENOMICS, 20(7), 407-413.

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
Gotlib, J., Berube, C., Growney, J. D., Chen, C. C., George, T. I., & Coutre, S. E. (2005). Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. BLOOD, 106(8), 2865-2870.